Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 September 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) has approved the first ultrasound device for use in women with dense breast tissue, marking a win for California-based U-Systems Inc.
The device, the somo-v Automated Breast Ultrasound System (ABUS), solves a previously intractable problem: How do you accurately detect a dense, tumorous mass when it is suspended in dense tissue?
FDA estimates approximately 40% of women have dense breasts, which makes mammograms difficult to interpret and can often lead to unnecessary testing or obscure an early-stage cancerous growth.
The device gets around the problem of breast density by scanning the entire breast, producing several images for a radiologist to review. Testing conducted by the company showed a statistically significant increase in the number of breast cancers detected using the somo-v system.
The device is only indicated for use on women who have a negative mammogram and no symptoms of breast cancer. FDA said it will require U-Systems to provide all facilities with user manuals on how to conduct regular quality-control measures.
Somo-v previously received unanimous support from FDA's Radiological Devices Panel, and has already received approval in Canada and the EU.
Read more:
FDA - FDA approves first breast ultrasound imaging system for dense breast tissue
U-Systems - somo•v Automated Breast Ultrasound (ABUS) System Receives FDA Approval for Breast Cancer Screening
Tags: U-Systems, ABUS, Mammogram, Breast, Latest News, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.